RadNet broadens AI focus with acquisitions of Aidence, Quantib

RadNet’s AI division has previously focused on breast imaging AI software, but the purchases of Quantib and Aidence will provide access to prostate, brain, and lung AI applications. A spin-off of Erasmus Medical Center, Rotterdam-based Quantib develops AI software for prostate and brain MRI. Meanwhile, Aidence has focused on utilizing AI for lung nodule management and lung cancer screening.

The goal is to apply these algorithms to facilitate new cancer screening programs for prostate and lung cancer, according to RadNet.

“With the addition of Aidence and Quantib, we will now have…